

AD _____

GRANT NUMBER DAMD17-96-1-6102

TITLE: TGF-alpha Expression During Breast Tumorigenesis

PRINCIPAL INVESTIGATOR: Kevin Taylor

CONTRACTING ORGANIZATION: University of Cincinnati
Cincinnati, Ohio 45221-0061

REPORT DATE: July 1997

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

DTIC QUALITY INSPECTED 2

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19971210 031

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE

July 1997

3. REPORT TYPE AND DATES COVERED

Annual (1 Jul 96 - 30 Jun 97)

4. TITLE AND SUBTITLE TGF-alpha Expression During Breast Tumorigenesis

5. FUNDING NUMBERS
DAMD17-96-1-6102

6. AUTHOR(S)

Kevin Taylor

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Cincinnati
Cincinnati, Ohio 45267-0529

8. PERFORMING ORGANIZATION
REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)

Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

10. SPONSORING/MONITORING
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200)

Transforming Growth Factor α (TGF α) is an oncogenic growth factor which drives estrogen-independent breast tumor proliferation via an autocrine loop. Its receptor, epidermal growth factor receptor (EGFR), is also a proto-oncogene, which in breast tumors may be overexpressed by gene amplification. In contrast, in normal breast TGF α and EGFR are expressed in an estrogen-dependent, cell-specific manner as part of an intercellular paracrine loop. The function of this paracrine loop is unknown. This proposal defines the role of TGF α /EGFR in the early steps of tumor progression prior to invasion by defining the cell-specific expression of TGF α and EGFR in normal and premalignant breast tissue. We have shown TGF α mRNA expression in eight breast cancer cell lines by either Northern blot analysis or in situ hybridization. In addition, we have shown TGF α protein expression by Western blot analysis in the eight cell lines and in freshly isolated tissue. Interestingly, fresh tissue samples express predominantly the soluble (6 kD) form of TGF α , unlike the cell lines which express mostly the transmembrane form of TGF α . Although more tissue samples are needed, this may indicate a difference in TGF α processing between transformed and non-transformed breast epithelium.

14. SUBJECT TERMS Breast Cancer

15. NUMBER OF PAGES

21

16. PRICE CODE

17. SECURITY CLASSIFICATION
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


~~____~~ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

~~____~~ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

7/30/57
Date

Year One of Predoctoral Award

TABLE OF CONTENTS

Front Cover	1
Standard Form (SF) 298	2
Foreword	3
Table of Contents	4
Introduction	5
Results	9
Discussion	11
Materials & Methods	12
Bibliographies	14
Figures	18

INTRODUCTION

Breast Cancer As a Process. The etiology of breast cancer can be defined in terms of the genetic changes which predispose breast epithelium to disregulated growth. These genetic changes may be inherited or the result of environmental insults. Regardless of the mechanism, these genetic changes result in the increased expression of oncogenes and the loss of expression of tumor suppressor genes, leading to uncontrolled proliferation (1-3). Endogenous estrogens are among the environmental influences which contribute to breast tumor development. Estrogens play a significant role in the normal growth and development of the breast (4). However, there is now little doubt that estrogenic stimulation of normal breast epithelial proliferation is central to the etiology of breast cancer development (5). Without estrogen, women do not get breast cancer. The mechanism by which estrogen-induced proliferation predisposes to specific genetic changes is not known. Furthermore, the mechanism of estrogen interaction with proto-oncogene products in normal breast tissue has not been extensively examined. This proposal focuses on the interaction of estrogen and one such proto-oncogene, transforming growth factor α (TGF α), during tumor development.

TGF α in Breast Tumorigenesis. Transforming Growth Factor α is commonly expressed at high levels in invasive breast cancer (6-8). This protein is a dominant oncogene, i.e. when overexpressed in breast epithelium, it produces a fully transformed cell (7-11). However, TGF α is also expressed at high levels in normal breast epithelium, and its synthesis is driven by estrogen (12-17). The function of TGF α in normal epithelium, therefore, appears to be quite different than that in tumor cells. Explaining this dichotomy is one goal of this proposal.

Many oncogenes encode growth factors, therefore the effects of growth factors in malignant cells have been well characterized (18). For instance, we know that the effects of growth factors (including TGF α) are dependent on the differentiated state of the cell, that is a growth factor which causes proliferation at one state of cellular differentiation may induce quiescence in a cell in another state (19). TGF α is expressed in normal epithelium, during pre-malignant proliferation, and in both in situ and invasive carcinoma (8, 20-21). Yet its function is clearly different over this progression to tumor formation. Understanding the role TGF α plays in normal and premalignant breast tissue is critical to understanding the mechanism through which TGF α mediates its effects in tumors.

Breast Histology. To understand the function of TGF α in the breast, one must understand normal breast histology. Breast

epithelium is composed of several epithelial cell types (22). Ducts are lined by luminal cells and myoepithelial cells. The luminal cells of the duct are thought to be involved in carcinogenesis (23). However, myoepithelial cells are occasionally transformed, also. This is not entirely surprising since myoepithelial and luminal cells are derived from the same stem cell population (24-25). For the most part, myoepithelial cells are not found in invasive carcinoma and when ducts are filled with carcinoma prior to invasion, at a stage called "in situ carcinoma," the myoepithelial cells are lost, or at best, greatly reduced in number (23). The milk-forming unit, or the lobule of the breast, is also composed of two epithelial cell types, alveolar cells and myoepithelial cells (22). The alveolar cells are the source of lobular carcinoma, a disease much less common than invasive ductal carcinoma (26). The lobular myoepithelial cells are morphologically similar to the ductal myoepithelial cells; however, biochemically they display some differences (our observations). Hormone-sensitive connective tissue composed of fibroblasts and myofibroblasts surrounds the epithelial cells of the breast. The role these cells play in the process of carcinogenesis is completely unknown. Each of these cell types expresses proto-oncogenes during the normal development and maturation of the breast. The regulation of this expression is the process which goes awry in tumorigenesis. To understand this regulation, we must examine the cell-specific expression of these proto-oncogenes and define the characteristics of normal breast which participate in this regulation.

Our preliminary data suggests that TGF α and its receptor (epidermal growth factor receptor or EGFR) function by two different mechanisms in normal breast. Here we show that the luminal cells of normal, quiescent breast epithelium express TGF α , but not EGFR; therefore, unlike tumor cells, the luminal cells can not respond to secreted TGF α in an autocrine fashion (Figure 1). Myoepithelial cells and adjacent stromal cells express EGFR normally; therefore, in normal breast the target for TGF α production is the myoepithelium and connective tissue. The cellular responses to this stimulation by TGF α are not known. Between quiescent epithelium and invasive tumor lie intermediate states of proliferation/transformation. Proliferative breast diseases of various morphologic types carries an increased risk of carcinoma and is considered a "pre-malignant" phenotype (27). In the literature and in our own experience, luminal EGFR expression is associated with some proliferative and cystic breast diseases (28). In particular, luminal cells with EGFR also express the estrogen receptor (ER) (28). Thus, alterations in EGFR synthesis may appear very early in proliferating breast, driven by estrogen. In fact, antisense studies with TGF α suggest

that induction of TGF α synthesis may be the main mechanism for estrogen-induced proliferation in this cell type (15). By the time breast epithelium has the characteristics of in situ carcinoma, TGF α and EGFR clearly co-localize in the luminal cells. The luminal cells up regulate EGFR and in the fully transformed state, respond to TGF α in an autocrine loop. At this stage there is an inverse correlation between EGFR and ER expression, consistent with the concept that over-stimulation of the TGF α /EGFR pathway leads to estrogen-independent growth (29). Some have suggested that cell transformation by EGFR is the result of a "threshold" level of EGFR expression (10). In this case, one would expect quantitatively increased expression in in situ carcinoma or invasive disease relative to these "pre-malignant" lesions. While the luminal cell is being driven to proliferate, the myoepithelial cell is lost during the transition from pre-malignant proliferative growth to in situ carcinoma. The mechanism by which these cells are lost, and the consequences of their loss are not known.

Here, we propose that TGF α effects on cells with luminal differentiation are proliferative; whereas, the effects on adjacent myoepithelium and connective tissue are to maintain cellular differentiation. The results of other investigations support this concept. First, MMTV-regulated TGF α expression in transgenic mice leads to uncontrolled luminal cell proliferation, with a normal relationship to myoepithelium. Cystic hyperplasias were particularly common in these animals, and development of adenocarcinoma was stochastic with time, consistent with TGF α functioning as a tumor promoter (30). Second, TGF α function is different depending on whether it acts via a paracrine or an autocrine mechanism. For instance, transfection with transmembrane TGF α leads to transformation whereas, exogenous TGF α , does not (11). Third, other extracellular molecules with TGF α -like domains are known to regulate differentiation through EGFR in many animals, including invertebrates (31). With myoepithelial differentiation, we believe the cells are no longer able to respond to TGF α by proliferation, and in fact that the function of TGF α on myoepithelium is to maintain cellular quiescence/differentiation. Conversely, myoepithelium is known to induce differentiation in breast cancer cell lines (32). Therefore, the presence of myoepithelium in breast tissue may be important in regulating luminal cell proliferation/differentiation. We propose that myoepithelial loss in tumor development results in loss of growth inhibitory signals which may or may not be related to TGF α /EGFR.

In this proposal we will explore the role of TGF α in normal and proliferative breast tissue. Understanding the normal role of TGF α in tumor production is critical for the following reasons. First, TGF α is a major estrogen-responsive gene (33); therefore, to understand estrogen-promotion of tumorigenesis, one must know the consequence of estrogen-induced gene expression. Second, TGF α function changes during the process of tumorigenesis. In normal tissue TGF α operates in a paracrine fashion and may be critical for maintaining normal lobular growth. In fact, there is now evidence that lactation is regulated by TGF α (34). However, in tumors TGF α leads to estrogen-independent growth (9). The effects of TGF α in the steps in between, from normal cell growth to invasive disease, have not been studied. Finally, current experimental therapies target various points in the TGF α signal transduction pathway. For instance, TGF α -EGFR stimulates cells through the MAP kinase pathway (35). This signal transduction pathway involves the proto-oncogene, ras, as well as two kinases which have been well characterized, protein kinase C (PKC) and protein kinase A (PKA) (36). The action of PKC is of particular note, since when EGFR is activated, it results in PKC activation (37-39). As part of an inhibitory feedback loop, PKC then phosphorylates and inhibits the action of EGFR, preventing over stimulation of the cell (40). These are exactly the types of pathways which one would predict are destroyed during the progression to malignancy. Current clinical trials include the use of Bryostatins, an agent which inhibits PKC (41). Given that TGF α can induce proliferation or differentiation, based on the differentiation state of the receptor cell, it is likely that the signaling pathways downstream of EGFR change during tumorigenesis. Therefore, it is critical that we understand the role TGF α is playing in specific breast cells at the time therapies affecting these pathways are instituted.

In this proposal, we build on our previous work, examining oncogene expression during tumor development and metastasis (Figure 1). Here we shall define the cell-specific expression of TGF α and EGFR in histologically similar premalignant states from women who do or do not progress to invasive tumor. Expression will be correlated with histopathologic types of proliferative breast disease, extent of disease types appearing concurrently, and estrogen receptor status. The observation that TGF α and EGFR must form a paracrine loop between myoepithelial and luminal cells is the result of careful evaluation of benign breast tissues for oncogene expression during a study comparing oncogene expression in benign, invasive, and metastatic tumors (43). In addition, the PI's mentor has collected an extensive set of premalignant breast tissue which are used for these studies. The results of this study will provide an invaluable database of

cell-specific gene expression in vivo which can then be correlated with in vitro tissue culture work.

RESULTS

1. Prepare riboprobes for in situ hybridization: subcloning of cDNAs, sequencing constructs. (Month 0-6).

The TGF α riboprobe was constructed by first subcloning 925 base pairs of TGF α cDNA (Genbank 190170) into the PGEM 3Z plasmid vector (Promega). Once cloned into PGEM vector, orientation and fidelity of cloning were verified by sequence analysis (Department of Molecular Genetics, Core Facility, University of Cincinnati College of Medicine, Cincinnati, Ohio). Sequence analysis showed the TGF α construct is oriented in the 5' to 3' direction relative to the T7 promoter in the vector. Therefore, transcription from the T7 promoter transcribes the antisense probe and SP6 transcribes the sense probe.

Conclusion: 925 base pairs of the TGF α gene has been sub-cloned into the PGEM 3Z plasmid and is in the 5' to 3' orientation relative to the T7 promoter.

2. Identify TGF α splice variants in breast cancer cell lines: Northern/RNase protection. (Month 6-9).

Initially, the riboprobe was labeled using the Genius Nonradioactive Nucleic Acid Labeling and Detection System (Boehringer-Mannheim Corp., Indianapolis, IN). The antisense TGF α digoxigenin labeled riboprobe was able to detect both the 4.8 kb and 1.6 kb mRNA transcripts on Northern blots of A431, and Hs-578-Bst, MDA-MB-453 cell lines (ATCC, Rockville, MD) (Figure 2). Due to the poor sensitivity of the digoxigenin labeled riboprobe (discussed in more detail under in situ hybridization section), labeling was switched from a nonradioactive to a radioactive method. The TGF α riboprobe is now labeled with ^{32}P -CTP according to a standard Promega protocol. To date, 25 RNA filters have been prepared and include the following eight breast cell lines: Hs-578 Bst, SKBR3, MCF-7, A431, T-47-D, MDA-MB-453, MDA-MB-468, and MCF-10A. These filters will be probed with the ^{32}P -UTP labeled TGF α riboprobe.

Conclusion: RNA filters on eight cell lines were prepared, and three of which have been probed with the digoxigenin labeled riboprobe. The three cell lines (A431, Hs-578-Bst, and MDA-MB-453) express the expected sized transcripts as quoted in the literature (44). Due to the insufficient sensitivity of the digoxigenin labeled probe a new ^{32}P -CTP labeled riboprobe was made and will be used to probe RNA filters on all eight cell lines.

3. Identify TGF α protein sizes in breast cell lines: Western blot. (Month 6-9).

Protein was isolated from the same eight cell lines from which RNA was isolated (see above) and Western blots performed. The blots were probed with an anti-TGF α antibody (213-4.4, Oncogene Research Products, Cambridge, MA), which detected both the transmembrane (approximately 21 kD) and the soluble (approximately 6 kD) forms as expected (Figure 3)(44). The primary form detected in these cell lines was the transmembrane bound form.

Conclusion: Protein was isolated from Hs-578 Bst, SKBR3, MCF-7, A431, T-47-D, MDA-MB-453, MDA-MB-468, and MCF-10A cell lines, and all predominantly express the transmembrane form.

4. Repeat 2 and 3 in normal breast cells or organoids (Northern and Western blots). (Month 9-12).

As mentioned previously, 25 RNA filters have been prepared. These filters include RNA from eight cell lines and six fresh tissue samples. In addition to the Westerns run on the eight cell lines, Westerns were also performed on cultured fibroblasts, and six fresh breast tissue specimens (Figure 3). Interestingly, unlike the cell lines or cultured fibroblasts, freshly isolated tissue expressed mostly the soluble (6 kD) form of TGF α . We are now doing experiments to see if this difference in TGF α protein expression is due to culturing of the cells (i.e. a culture artefact), or if an underlying difference exists between transformed versus non-transformed epithelial cells.

Conclusion: Both RNA and protein were isolated from six fresh tissue samples. RNA filters have been prepared on tissue samples and are waiting to be probed. Western blots were performed on protein isolated from both cultured fibroblasts and fresh tissue specimens. The fresh tissue specimens expressed mostly the soluble form of TGF α , while cultured fibroblasts expressed mostly the transmembrane form.

5. Develop splice-specific probes: subcloning/RT-PCR. (Month 9-12).

Due to the poor sensitivity of the digoxigenin labeled riboprobes we are repeating our Northern blots using ³²P labeled probes. To date, no potential splice variants have been identified.

6. Examine normal and proliferative breast tissue for cell-specific expression of TGF α : in situ hybridization and RT-PCR. (Month 12-24).

Paraffin embedded tissue from 90 patients have been collected and characterized. TGF α and EGFR immunohistochemistry have been performed on all samples. These data are now being analyzed. A digoxigenin-labeled riboprobe was prepared for in situ hybridization and showed good hybridization using paraffin embedded cell blocks of TGF α producing A431 cells (Figure 4). However, based on our observations and those of others the low level incorporation of digoxigenin-labeled UTP made the sensitivity of the probe insufficient to be used for in situ hybridization on paraffin embedded tissues. Serial dilution experiments indicated we were only able to consistently identify 100 or more picograms of riboprobe (data not shown). The literature indicates a detection level of 0.1 picograms for in situ hybridization is required(44). Thus, to improve the sensitivity of our riboprobe we are now labeling with ³⁵S-UTP. Conclusion: In situ Hybridization of digoxigenin labeled probe detected TGF α mRNA in A431 cells, but is not sensitive enough to perform ISH on paraffin embedded tissues. Work with radioactive probes is in progress.

7, 8, & 9.

These are goals for future years and are not addressed at this time.

DISCUSSION

We have subcloned 925 basepairs of the TGF α gene into the PGEM 3Z plasmid and have made digoxigenin-labeled riboprobes. The antisense probe specifically identified TGF α mRNA in paraffin embedded A431 cells. However, due to the insufficient sensitivity, riboprobes are now labeled with either ³⁵S-UTP (in situ hybridization) or ³²P (Northern blot). Twenty-five RNA filters have been prepared from eight cell lines (Hs-578 Bst, SKBR3, MCF-7, A431, T-47-D, MDA-MB-453, MDA-MB-468, and MCF-10A) and six fresh breast tissue specimens. Northern blots probed with the digoxigenin labeled TGF α riboprobe identified both the 4.8 kb and 1.6 kb TGF α mRNA in three cell lines (A431, Hs-578 Bst, & MDA-MB 453).

Protein was isolated from the same eight cell lines from which RNA was isolated (see above) and Westerns performed. Westerns were also performed on freshly isolated tissue and cultured breast fibroblasts. To date, there is Western data on eight cell lines, 1 sample of fibroblasts, and five samples of fresh tissue. The cell lines and the fibroblasts expressed mostly the transmembrane form of TGF α , while the fresh tissue expressed mostly the soluble form. This difference in TGF α protein expression may be due to adaptive mechanisms from long term in

vitro culture conditions, or may reflect difference in transformed versus non-transformed epithelial cells. In either circumstance, more data need to be obtained, including testing conditioned media from cultured cell lines and comparing matched samples of freshly isolated organoids and after short term culture.

Lastly, we have histologically characterized 90 paraffin embedded breast tissue samples. TGF α and EGFR IHC has been performed on all samples and the data are now being analyzed. These data should provide meaningful information TGF α and EGFR expression during tumorigenesis in breast epithelium.

MATERIALS & METHODS

Tumor cell culture: Breast tumor cell lines Hs-578 Bst, SKBR3, MCF-7, A431, T-47-D, MDA-MB-453, MDA-MB-468, and MCF-10A were obtained from ATCC and cultured according to their protocols. Cells are passaged weekly using trypsin-EDTA.

Organoid isolation: Breast epithelium (organoids) is dissected from both mastectomy and reduction mammoplasty specimens, minced, and enzymatically digested with collagenase as previously described (45). Briefly, tissue is obtained within 1 hour of surgery, minced with opposing scalpels to 1 mm³ pieces, and enzymatically digested for 12 to 18 hours at 37 °C in a rotary shaker (60 rpm) with 150 U/ml Collagenase Type I (Gibco), 100 U/ml Hyaluronidase (Gibco) in CDM3 media. CDM3 media consists of DMEM/f12 (1:1), 2.6 ng/ml selenium, 100 ng/ml EGF, 0.1 µg/ml fibronectin (all from Collaborative Research, Bedford, MA), 3 µg/ml insulin, 25 µg/ml transferrin, 10⁻¹⁰ M estradiol, 10⁻⁶ M hydrocortisone, 10⁻⁸ M cAMP, 10⁻⁸ M triiodothyronine, 10⁻⁴ M ethanolamine, 10⁻⁴ M phosphoethanolamine, 0.1% BSA, 10 µg/ml ascorbic acid, 20 µg/ml fetuin (all from Sigma, St. Louis, MO), and 1X trace element mix (Biofluids, Rockville, MD). Following digestion, epithelial organoids and fibroblasts are separated from vascular fragments and from one another by sedimentation.

Non-radioactive labeling of riboprobe: cDNA in the PGEM 3Z plasmid is linearized by restriction enzymes: BAMH1 for the sense probe yielding a 767 basepair fragment, and APA1 for the antisense probe yielding a 734 basepair fragment. 1 µg of linearized template was added to 10mM ATP, 10 mM GTP, 10 mM CTP, 6.5 mM UTP, and 3.5 mM digoxigenin labeled UTP, 20 Units of T7 and Sp6 Polymerase each in 40 mM Tris-HCl pH 8.0, 6 mM MgCl₂, 10 mM dithioerythritol (DTE), 2 mM spermidine, 10 mM NaCl, and 0.1 U/ml RNase inhibitor. The reaction mixture is incubated for 12 hours at 37 °C and the reaction is terminated by adding RQ1 RNase-free DNase for 15 minutes at 37 °C. The riboprobe is isolated by phenol-chloroform extraction and ethanol precipitation.

Estimating yield of digoxigenin labeled nucleic acids: The riboprobe is serially diluted and spotted onto a Magna Graph Nylon Transfer Membrane (MSI Inc., Westboro, MA). Once dry the nucleic acids are cross-linked to the membrane by a brief exposure to UV. The Genius 3 Nucleic Acid Detection Kit (Boehringer-Mannheim) is used to identify the riboprobe. Briefly, the membrane is soaked in Blocking Reagent (Boehringer-Mannheim) for 5 minutes, incubated for 10 minutes with the anti-digoxigenin alkaline phosphatase antibody diluted 1:5,000 in Blocking Reagent, washed two times with washing buffer (10 mM Maleic acid; 15 mM NaCl, pH 7.5) for 5 minutes each, and color substrate is developed using a nitroblue tetrazolium (NBT)/X-phosphate solution. The intensity of staining is then compared to the staining of a known amount of dig-labeled nucleic acid.

Northern Blot Analysis. Total cellular RNA is isolated using RNazol (CINNA/BIOTEX) and electrophoresed on formaldehyde-denatured agarose gels as in (65). RNA is transferred onto Nytran for hybridization. Prehybridization of the filters is carried out for 4-18 hours at 37°C in 50% formamide, 5x SSC, 0.1% polyvinylpyrrolidone, 0.1% Ficoll, 0.1 mg/ml salmon sperm DNA, 20 mM sodium phosphate (pH 6.8), and 0.1% SDS. For hybridization the appropriate 5'-end labeled oligonucleotide or ³²P-labelled riboprobe is added and incubated at 37° overnight. The filters are then washed in 2x SSC and 1% SDS twice at room temperature, 2x SSC and 1% SDS twice at 37°C, and 0.2x SSC and 1% SDS for 15 minutes at 37°C.

In situ hybridization. The riboprobe is degraded to 100-200 base lengths and dissolved at 3 ng/μl/kb length of cloned fragment in hybridization buffer with 20mM DTT, prior to use. Hybridization is carried out on dewaxed tissue sections at 55° overnight in 50% formamide, 0.3M NaCl, 20mM Tris-HCl, pH 8.0, 5mM EDTA, 10mM NaPO₄, pH 8.0, 10% dextran sulphate, 1x Denhardt's, 0.5 mg/ml yeast RNA. Slides are then washed in 50% formamide, 2x SSC, 10mM DTT at 65° for 30'; 0.5M NaCl, 10mM Tris, pH 7.5, 5mM EDTA at 37° 4 times, once including 20μg/ml RNase; and then in 2xSSC, and 0.1xSSC for 15' each at room temperature. Slides are then dehydrated and prepared for autoradiography using Kodak NTB-2 nuclear track emulsion, Kodak Developer D19, and Kodak ammonium fixer. Slides are generally developed after one week and counterstained with nuclear fast red.

Western blot: Cells or tissues are homogenized in 20mM Tris-HCl, pH 7.4, 2mM EDTA, 0.5mM EGTA for protein analysis (Bradford assay) and then electrophoresed under reducing conditions on 10% acrylamide SDS-PAGE (Laemmli) and transferred to PVDF membranes (Millipore) by the Towbin method. Membranes from each well are cut for replicate analysis, blocked in 5% non-fat dry milk, 0.5M NaCl, 10 mM Tris-HCl, pH 7.5. Primary antibodies (5-10 μg/ml) are incubated in blocking solution at RT overnight. The membranes are washed and incubated one hour at RT with biotinylated anti-

mouse/rabbit Ig (1:100, Sigma), washed, and incubated another hour with Streptavidin-alkaline phosphatase (1:200, Sigma) in 5% non-fat milk, 150 mM NaCl, 50 mM Tris-HCl, pH 7.5. The reaction is developed with BCIP/NBT substrate. Samples are calibrated for equal loading by using antibodies against actin.

BIBLIOGRAPHY

1. Lee EY-HP, Tumor suppressor genes and their alterations in breast cancer. Sem in Cancer Biology. 6:119-125, 1995.
2. Eufjord JE, Thorlacium S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir HM, Ananthawat-Jonssoon K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55:646-651, 1995.
3. van Leeuwen F, Nusse R. Oncogene activation and oncogene cooperation in MMTV-induced mouse mammary cancer. Sem in Cancer Biol. 6:127-133, 1995.
4. Richards JE, Shyamala G, Nandi S. Estrogen receptor in normal and neoplastic mouse mammary tissues. Cancer Res 34:2764-2772, 1974.
5. Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrine Rev. 8:29-43, 1987.
6. Salomon DS, Kim N, Saeki T, Ciardiello F. Transforming growth factor α : an oncodevelopmental growth factor. Cancer Cells 2:389-397, 1990.
7. Madsen MW, Lyddesfeldt AE, Laursen I, Nielsen KV, Briand P. Altered gene expression of c-myc, epidermal growth factor receptor, transforming growth factor- α , and c-erb-B2 in an immortalized human breast epithelial cell line, HMT-3522, is associated with decreased growth factor requirements. Cancer Res. 52:1210-1217, 1992.
8. Perroteau I, Salomon D, DeBortoli M, Kidwell W, Hazarika P, Pardue R, Dedman J, Tam J. Immunological detection and quantitation of alpha transforming growth factors in human breast carcinoma cells. Breast Cancer Res and Treat. 7:201-210, 1986.
9. Herman ME, Katzenellenbogen BS. Alterations in transforming growth factor- α and - β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54:5867-5874, 1994.
10. DiMarco E, Pierce JH, Fleming TP, Kraus MH, Mollay CJ, Aaronson SA, Di Fiore PP. Autocrine interaction between TFG α and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4:831-838, 1989.
11. Ju WD, Velu TJ, Vass WC, Papageorge AG, Lowry DR. Tumorigenic transformation of NIH 3T3 cells by the autocrine synthesis of transforming growth factor α . New Biol. 3:380-388, 1991.

12. Spitzer E, Zschesche W, Binas B, Grosse R, Erdmann B. EGF and TGF α modulate structural and functional differentiation of the mammary gland from pregnant mice in vitro: possible role of the arachidonic acid pathway. *J Cell Biochem.* 57:495-508, 1995.
13. Zwiebel JA, Bano M, Nexo E, Salomon DS, Kidwell WR. Partial purification of transforming growth factors from human milk. *Cancer Res.* 46:933-939, 1986.
14. Liu SC, Sanfilippo B, Perroteau I, Derynck R, Salomon DS, Kidwell WR. Expression of transforming growth factor α (TGF α) in differentiated rat mammary tumors: estrogen induction of TGF α production. *Molec Endocrin.* 1:683-692, 1987.
15. Kenney NJ, Saeki T, Gottardis M, Kim N, Garcia-Morales P, Martin MB, Normanno N, Ciardiello F, Day A, Cutler ML, Salomon DS. Expression of transforming growth factor α antisense mRNA inhibits the estrogen-induced production of TGF α and estrogen-induced proliferation of estrogen-responsive human breast cancer cells. *J Cell Physiol.* 156:497-514, 1993.
16. Manni A, Wright C, Gadger B, Bartholomew M, Herlyn M, Mendelsohn, Masui H, Demers L. Role of transforming growth factor- α -related peptides in the autocrine/paracrine control of experimental breast cancer growth in vitro by estradiol, prolactin, and progesterone. *Breast Cancer Res and Treat.* 15:73-83, 1990.
17. Saeki T, Cristiano A, Lynch MJ, Brattain M, Kim N, Normanno N, Denney N, Ciardiello F, Salomon DS. Regulation by estrogen through the 5'-flanking region of the Transforming Growth Factor α gene. *Molec Endocrin.* 5:1955-1963, 1991.
18. Druker BJ, Mamon HJ, Roberts TM. Oncogenes, growth factors, and signal transduction. *New Engl J Med.* 321:1383-1391, 1989.
19. Sauma S, Huang F, Winawer S, Friedman E. Colon goblet cells lose proliferative response to TGF α as they differentiate. *Int J Cancer* 61:848-853, 1995.
20. Snedeker SM, Brown CF, DiAugustine RP. Expression and functional properties of transforming growth factor α and epidermal growth factor during mouse mammary gland ductal morphogenesis. *Proc Natl Acad Sci USA.* 88:276-280, 1991.
21. Scala S, Saeki T, Lynch A, Salomon D, Merino MJ, Bates SE. Coexpression of TGF α , epidermal growth factor receptor, and P-glycoprotein in normal and benign diseased breast tissues. *Diagnostic Molec Pathol.* 4:136-142, 1995.
22. Rudland PS. Histochemical organization and cellular composition of ductal buds in developing human breast: evidence of cytochemical intermediates between epithelial and myoepithelial cells. *J Histochem and Cytochem.* 39:1471-1484, 1991.

23. Rudland PS, Leinster SJ, Winstanley J, Green B, Atkinson M, Zakhour HD. Immunocytochemical identification of cell types in benign and malignant breast diseases: variations in cell markers accompany the malignant state. *J Histochem Cytochem.* 41:543-553, 1993.
24. Rudland PS, Barraclough R. Stem cells in mammary gland differentiation and cancer. *J Cell Sci Suppl* 10:95-114, 1988.
25. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of solitary intraductal papilloma of the breast by means of polymerase chain reaction. *Am J Pathol* 144:1320-5, 1994.
26. Silverstein MJ, Lewinsky BS, Waismann JR, Gierson ED, Colburn WJ, Senofsky GM, Gamagami P. Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? *Cancer* 73:1673-1677, 1993.
27. Bodian CA, Perzin KH, Lattes R, Hoffmann P, Abernathy TG. Prognostic significance of benign proliferative breast disease. *Cancer* 71:3896-3907, 1993.
28. van Agthoven T, Timmermans M, Foekens JA, Dorssers LCJ, Henzen-Logmans SC. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. *Am J Pathol.* 144:1238-1246, 1994.
29. Newby JC, A'Hern RP, Leek RD, Smith IE, Harris AL, Dowsett M. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. *Br J Cancer* 71:1237-1242, 1995.
30. Halter SA, Dempsey P, Matsui Y, Stokes MK, Graves-Deal R, Hogan BLM, Coffey RJ. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor- α . *Am J Pathol.* 140:1131-1146, 1992.
31. Smas CM, Sui HS. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. *Cell* 73:725-734, 1993.
32. Bani D, Riva A, Bigazzi M, Sacchi TB. Differentiation of breast cancer cells in vitro is promoted by the concurrent influence of myoepithelial cells and relaxin. *Br. J. Cancer.* 70:900-904, 1994.
33. Bates SE, Danidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS. Expression of transforming growth factor α and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. *Molec Endocrinol.* 2:543-555, 1988.
34. Lin CQ, Dempsey PJ, Coffey RJ, Bissell MJ. Extracellular matrix regulates whey acidic protein gene expression by suppression of TGF α in mouse mammary epithelial cells:

- studies in culture and in transgenic mice. *J Cell Biol.* 129:1115-1126, 1995.
35. Ahn NG, Seger R, Bratlien RL, Keltz CD, Tonks NK, Krebs EG. Multiple components in an epidermal growth factor-stimulated protein kinase cascade. *J Biol Chem.* 7:4220-4227, 1991.
 36. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2, adaptor protein, and Sos nucleotide exchange factor. *Cell* 73:611-620, 1993.
 37. Osborne CK, Hamilton B, Nover M, Ziegler J. Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. *J Clin Invest.* 67:943-951, 1981.
 38. Fabbro D, Kung W, Roos W, Regazzi R, Eppenberger U. Epidermal growth factor binding and protein kinase C activities in human breast cancer cell lines: possible quantitative relationship. *Cancer Res.* 46:2720-2725, 1986.
 39. Wyss R, Fabbro D, Regazzi R, Borner C, Takahashi A, Eppenberger U. Phorbol ester and epidermal growth factor receptors in human breast cancer. *Anticancer Res.* 7:721-728, 1987.
 40. Schlessinger J. Allosteric regulation of the epidermal growth factor receptor kinase. *J Cell Biol.* 103:2067-2072, 1986.
 41. Blobel GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. *Cancer and Met Rev.* 13:411-431, 1994.
 42. Lower E, Heffelfinger SC, Miller MA, Fenoglio-Preiser CM. Phosphotyrosine immunoreactivity is a significant prognostic indicator in breast carcinoma patients. *Breast Cancer Res Treat.* 35:277-282, 1995.
 43. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal Growth Factor-related peptides and their receptors in human malignancies. *Critical Review in Oncology/Hematology*, 19:183-232, 1995.
 44. Lan HY, Wei Mu, Yee YY, Nikolic-Patterson DJ, Atkins RC. A simple, reliable, and sensitive method for nonradioactive In Situ Hybridization: Use of Microwave Heating to Improve Hybridization Efficiency and Preserve Tissue Morphology. *The Journal of Histochemistry and Cytochemistry* 44:281-287, 1996.
 45. Petersen OW, vanDeurs B. Preservation of Defined Phenotypic Traits in Short-Term Cultured Human Breast Carcinoma Derived Epithelial Cells. *Cancer Research* 47:856-862, 1987.

FIGURES

Figure 1. (a) immunohistochemistry showing TGF α is normally expressed in the luminal epithelial cells, (b) immunohistochemistry showing EGFR is normally expressed in the myoepithelial cells.





Figure 2. Northern blots (T7 is antisense probe) showing expression of TGF α mRNA using a digoxigenin-labeled riboprobe. (a) 4.8 kb and 1.6 kb TGF α mRNA is expressed in A431 cells, (b) Hs-578-Bst cells, and (c) MDA-MB-453 cells.

A

T7



4.8 kb


1.6 kb

B

HTB126

T7


SP6



4.8 kb

1.6 kb

C



1.6 kb

4.8 kb

T7

SP6

HTB131

Figure 3. Western blot of protein isolated from both cell lines and fresh breast tissue samples. Lanes are protein isolated from: (a) TGF α , (b) SKBR3 cells, (c) MCF-7 cells, (d) Hs-578 Bst, (e) MDA-MB 453, (f) MDA-MB-468, (g) T-47 D, (h) cultured fibroblasts, (i) MCF-10A, (j) freshly isolated breast organoids, and (k) TGF α .




Figure 4. In situ hybridization with digoxigenin-labeled TGF α riboprobe in A431 cells. (a) antisense probe hybridizing to TGF α mRNA, (b) sense probe.

